Diabetes Obesity & Metabolism

Article	Citations
COVID‐19 infection may cause ketosis and ketoacidosis	325
Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysis	295
Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis	191
Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID‐19	180
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension	175
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications	142
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update	142
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity	132
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study	118
The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single‐centre, retrospective, observational study in Wuhan	116
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review	105
Prediabetes and the risk of heart failure: A meta‐analysis	103
Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials	95
Influence of diabetes mellitus on the severity and fatality of SARS‐CoV‐2 (COVID‐19) infection	90
Hybrid closed‐loop therapy: Where are we in 2021?	87
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis	86
Exposure to dipeptidyl‐peptidase‐4 inhibitors and COVID‐19 among people with type 2 diabetes: A case‐control study	82
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk	80
Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users	79
Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome	78
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes	78
Why is hyperglycaemia worsening COVID‐19 and its prognosis?	72
Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study	71
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme	66
Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials	65

Relationship between obesity and severe COVID‐19 outcomes in patients with type 2 diabetes: Results from the CORONADO study	63
Obesity as a risk factor for COVID‐19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease	62
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study	61
The PREVIEW intervention study: Results from a 3‐year randomized 2 x 2 factorial multinational trial investigating the role of protein, glycaemic index and physical activity for prevention	60
Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study	59
Association of obesity with postacute sequelae of COVID‐19	58
Hybrid closed‐loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double‐blind, multicentre, multinational, randomized, crossover st	57
A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know	56
Association between prediabetes and adverse outcomes in heart failure	55
Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials	55
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials	54
The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective	52
Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested posi	52
The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc	52
Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study	51
Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes	51
Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta‐analysis	48
Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, ran	47
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study	47
Diabetes, obesity and COVID‐19: A complex interplay	47
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system	47
Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlle	46
COVID‐19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission	46
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study	45
Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study	45
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin	44
Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis	43
Intermittent fasting and ‘metabolic switch’: Effects on metabolic syndrome, prediabetes and type 2 diabetes	43
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A	43
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications	41
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials	41
Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes	40
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study	40
Semaglutide for the treatment of overweight and obesity: A review	39
Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes	39
Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (United States) and the prospective diabetes follow‐up (Germany/Austria) registries	39
Effects of the COVID‐19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study	39
Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis	38
COVID‐19, ketoacidosis and new‐onset diabetes: Are there possible cause and effect relationships among them?	37
Add‐on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study	37
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective	37
Real‐world performance of the MiniMed™ 670G system in Europe	37
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial	37
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study	37
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes	36
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial	36
Technology in the management of type 2 diabetes: Present status and future prospects	36
Global mortality of diabetic foot ulcer: A systematic review and meta‐analysis of observational studies	36
Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review	35
C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective	35

Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation	35
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials	35
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis	35
Sodium‐glucose co‐transporter‐2 inhibitors and major adverse limb events: A trial‐level meta‐analysis including 51 713 individuals	35
Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality	35
Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, mul	35
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phas	34
Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study	34
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss	34
A phase 3 randomized clinical trial using a once‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity	34
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes	33
Sodium‐glucose co‐transporter‐2 inhibitors and all‐cause mortality: A meta‐analysis of randomized controlled trials	32
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER	32
Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta‐analysis	31
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial	31
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial	31
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease	31
Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26‐week randomized controlled trial; mechanisms of weight loss	31
An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight	31
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment	31
Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID‐19: A population‐based retrospective cohort study	31
Sodium‐glucose co‐transporter‐2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis	31
Risk of new‐onset type 2 diabetes in 600 055 people after COVID‐19: A cohort study	31
Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study	31
Machine‐learning–based early prediction of end‐stage renal disease in patients with diabetic kidney disease using clinical trials data	31
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus trea	30
Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence	30
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison	29
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses	29
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, doubl	28
Real‐world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed‐loop use	28
Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta‐analysis with meta‐regression	28
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study	28
Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)	27
Greater variability in lipid measurements associated with cardiovascular disease and mortality: A 10‐year diabetes cohort study	27
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized con	27
The J‐shaped relationship between body mass index and mortality in patients with COVID‐19: A dose‐response meta‐analysis	27
Body mass index and the risk of COVID‐19 across ethnic groups: Analysis of UK Biobank	27
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide	27
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2	26
New insights into the treatment of obesity	26
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial	26
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline cha	26
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta‐cell protection in type 1 diabetes	26
Metformin‐induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes	26
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes	26
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial	26
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study	25
Metabolically healthy obesity and cardiovascular events: A nationwide cohort study	25
Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan	25
Effects of hyperglycaemia on complications of COVID‐19: A meta‐analysis of observational studies	25
Metabolic surgery for the treatment of type 2 diabetes: A network meta‐analysis of randomized controlled trials	25
HbA1c and brain health across the entire glycaemic spectrum	25
Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: A cross‐sectional and longitudinal study from the <	25
Admission fasting blood glucose predicts 30‐day poor outcome in patients hospitalized for COVID‐19 pneumonia	25
Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9‐39) for treatment of post‐bariatric hypoglycaemia	25
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus	24
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic	24
The impact of the COVID‐19 pandemic on glycaemic control in people with diabetes: A systematic review and meta‐analysis	24
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment	24
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial	24
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes	24
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58	24
Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study	23
Obesity as a driver of international differences in COVID‐19 death rates	23
Performance of a factory‐calibrated, real‐time continuous glucose monitoring system during elective abdominal surgery	23
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2	23
A real‐world study of user characteristics, safety and efficacy of open‐source closed‐loop systems and Medtronic 670G	23
Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults	23
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States	23
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabet	23
Validation of obesity‐related diagnosis codes in claims data	22
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review	22
The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apop	22
Current trends in diabetes mellitus database research in Japan	22
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906	22
Association between visit‐to‐visit HbA1c variability and the risk of cardiovascular disease in patients with type 2 diabetes	22
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial	22
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless	22
Effects of sodium‐glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta‐analysis	22

Effects of a 6‐month, low‐carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes: An open‐label randomized controlled trial	22
The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men	22
Ultra‐rapid‐acting insulins for adults with diabetes: A systematic review and meta‐analysis	22
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial	22
Association of lactation with maternal risk of type 2 diabetes: A systematic review and meta‐analysis of observational studies	22
Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study	22
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis	21
Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes	21
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies	21
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity	21
Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial	21
Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐we	20
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with	20
Impact of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: A randomized clinical trial	20
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Ita	20
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial	20
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events	20
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11	20
Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019	20
Risk of diabetic macular oedema with sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes patients: A multi‐institutional cohort study in Taiwan	20
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes	19
Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations	19
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A meta‐analysis and meta‐regression analysis	19
Metabolic surgery: A clinical update	19
Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose‐ranging study	19
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon‐like peptide‐1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants	19
Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS‐HFDM	19
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes	19
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence	19
Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11):	19
Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial	18
Longevity of the novel ConvaTec infusion set with Lantern technology	18
Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed‐loop insulin delivery system: A series of N‐of‐1 randomized controlled trials	18
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month	18
Glucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying	18
The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial	18
ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes	18
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	18
Reducing the need for carbohydrate counting in type 1 diabetes using closed‐loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non‐inferiority, crossove	17
Vitamin D for treatment of non‐alcoholic fatty liver disease detected by transient elastography: A randomized, double‐blind, placebo‐controlled trial	17
Combined therapy with CD4+CD25highCD127− T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Ra	17
Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by 18F‐labelled fluorodeoxyglucose positron emission tomography‐MRI	17
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes	17
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electro	17
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia	17
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials	17
Changes in the use of glucose‐lowering drugs: A Danish nationwide study	17
Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel	17
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double‐blind, placebo‐controlled phase 3a clinical trial	17
Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial	17
Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection	17
Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniM	17
Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta‐analysis	17
Effectiveness of a closed‐loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: A prospective, multicentre, real‐life study	17
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data	17
Completion of annual diabetes care processes and mortality: A cohort study using the National Diabetes Audit for England and Wales	16
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controll	16
Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States	16
Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke	16
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries	16
The impact of the glucagon‐like peptide‐1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes	16
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER an	16
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro	16
Change in glucose‐lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID‐19 pandemic in Germany	16
Beneficial actions of a long‐acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation	16
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the ra	16
Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms	16
Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials	16
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomi	15
Exendin(9‐39)NH2: Recommendations for clinical use based on a systematic literature review	15
A global country‐level analysis of the relationship between obesity and COVID‐19 cases and mortality	15
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials	15
Using machine learning to predict severe hypoglycaemia in hospital	15
Distribution patterns of intramyocellular and extramyocellular fat by magnetic resonance imaging in subjects with diabetes, prediabetes and normoglycaemic controls	15
Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy	15
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease	15
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes	15
Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID‐19 patients with diabetes: A population‐based study in Lombardy	15
High‐dose sodium‐glucose co‐transporter‐2 inhibitors are superior in type 2 diabetes: A meta‐analysis of randomized clinical trials	15
Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?	15
In‐home use of a hybrid closed loop achieves time‐in‐range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial	15
Insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review	15
The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials	15
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function	15
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial	15
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden	15
Effect of the glucagon‐like peptide‐1 analogue liraglutide versus placebo treatment on circulating proglucagon‐derived peptides that mediate improvements in body weight, insulin secretion and action:	15
Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes	14
Dietary fibre intake in childhood or adolescence and subsequent health outcomes: A systematic review of prospective observational studies	14
Sodium‐glucose co‐transporter‐2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta‐analysis	14
Risk of developing diabetes in patients with atrial fibrillation taking non‐vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study	14
Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?	14
Effects of whey protein plus vitamin D supplementation combined with progressive resistance training on glycaemic control, body composition, muscle function and cardiometabolic risk factors in middle‐	14
A second‐generation glucagon‐like peptide‐1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models	14
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?	14